Lumida
/AXON
⌘K
Axon Enterprise Inc

Axon Enterprise Inc

AXON
$510.28USD-5.81%-31.47 today

MARKET CAP

41.1B

P/E (TTM)

72.4x

FWD P/E

55.5x

DAY RANGE

$507 – $538

52W RANGE

$339
$886

AI Summary

Stalk
StalkMedium

AXON remains in a Stage 2 advancing uptrend and above the rising 50 DMA, but recent attempts failed to exceed the July high and price has been rejected at the flattened 9 EMA/21 EMA. Short-term momentum is down, making immediate entry unfavorable. We will stalk for a pullback into the short-EMA zone or support at the rising 50 DMA before considering a long execution.

  • Q1 2026 revenue reached $807 M (+34% YoY), marking nine quarters above 30% growth
  • AI product revenue grew over 700% YoY, driving faster customer adoption
  • Negative earnings yield and low book-to-price indicate high valuation risk
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Axon Enterprises, Inc. (NASDAQ: AXON) specializes in public safety technology, providing a comprehensive suite of solutions encompassing body cameras, TASER devices, and AI-driven software services, all designed to enhance the operational effectiveness and safety of law enforcement agencies globally. The company is pivoting towards an AI-driven ecosystem, capitalizing on technological advancements to optimize data connectivity and real-time support. This positions Axon as a leading innovator in transitioning public safety practices through seamlessly integrated solutions.

Bull says

  • Q1 2026 revenue reached $807 M (+34% YoY), marking nine quarters above 30% growth
  • AI product revenue grew over 700% YoY, driving faster customer adoption
  • Record bookings topped $7 B (+75% YoY) with future contracted bookings at $14.3 B (+44% YoY)
  • Free cash flow forecast ~$450 M for FY 2026 and adjusted EBITDA margin of 25%
  • Low leverage risk and strong profitability position Axon to benefit from rising rates
  • Acquisitions of Prepared and Carbine expand AI-driven 911 response capabilities

Bear says

  • Negative earnings yield and low book-to-price indicate high valuation risk
  • R&D expenses and tariffs pressure operating margins near current 25% EBITDA
  • Weak price momentum and heightened volatility may deter investors
  • Regulatory and ethical risks around AI use and government contracts could impair reputation
  • High customer concentration and federal spending reliance expose revenue to political shifts
  • Analyst earnings revisions trending lower, reflecting market skepticism

Investment themes with AXON

Defense -0.89%

Military equipment and defense contractors

BWXT · RKLB · CRS
Drones -2.03%

Unmanned aerial vehicles and related technology

AVAV · ONDS · RCAT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026bullish

Transcript signals

Bull points

  • We're heads down working on integrating and maximizing the potential of all the acquisitions we've made over the last couple of years, and there's been a bunch of them. So I think, Alex, this is a year where, of course, we'll be opportunistic. Of course, we'll continue to invest in other companies that we think could be great partners or future acquisition targets. But really for this year, it's about going into execution mode, integrating the acquisitions we've made very, very well, and putting up more results like we're seeing out of D-Drone, Fusis, and our 911 business right now.
  • When the war is over, we think there's going to be a lot of go-to-market opportunities where we might be able to bring that tech, you know, into other markets.
  • Revenue of $807 million was up 34% year-over-year and marks our ninth consecutive quarter of growth above 30%.

Bear points

  • As we scale the business, we are also focusing on our free cash flow conversion from adjusted EBITDA. Josh talked about the continued investments we're making in inventory this year, which you can see in Q1.
  • software and services standpoint. Software and services tends to be very lumpy. I think what we saw here is sequentially probably a little bit lower than what we were expecting
Read full transcript analysis ›